Advaxis, Inc.
Advaxis, Inc. is a late-stage biotechnology company developing cancer immunotherapies that enlist the body’s immune system to fight cancer. Our platform technology – Lm Technology – alters a live strain of Listeria monocytogenes bacteria to generate cancer-fighting T cells directed against cancer antigens and modulates the tumor microenvironment to overcome immune suppression. We have four franchises in various stages of development: HPV-associated cancers, personalized neoantigen therapy, disease focused hotspot/ cancer antigen therapy and prostate cancer. Visit www.advaxis.com